By Erin McCarthy
Actavis PLC (ACT) said Thursday that a U.S. federal court has
ruled that its generic version of Novartis' Exelon Patch infringes
certain patents.
Exelon Patch is a prescription medicine used to treat people
with mild to moderate dementia associated with Alzheimer's or
Parkinson's disease.
Actavis said in a statement that it is reviewing the decision of
the U.S. District Court for the District of Delaware and will
evaluate all available options, including an appeal.
Actavis' new drug application for its generic version of Exelon
Patch is currently pending with the U.S. Food and Drug
Administration, the company said.
Earlier this month, Vivus Inc. (VVUS) said it filed a
patent-infringement lawsuit against Actavis PLC (ACT) alleging that
the drug maker's planned generic version of weight-loss drug Qsymia
infringes its patents.
Write to Erin McCarthy at erin.mccarthy@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires